Tapering off of long-term use of acid suppressant drugs is possible;Afbouw van langdurig gebruik van maagzuurremmers is mogelijk

Huisarts en Wetenschap

Volumn 46, Issue 7, 2003, Pages 354-358

  Hurenkamp, G J B ^a   Grundmeijer, H G L M ^a   Van Der Ende, A ^c   Tytgat, G N J ^c   Assendelft, W J J ^c   Van der Hulst, R W M ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Infection and Immunology   (Netherlands)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; PROTON PUMP INHIBITOR; SEROTONIN 2 ANTAGONIST; STOMACH SECRETION INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE; DRUG USE; DRUG WITHDRAWAL; DYSPEPSIA; GASTROESOPHAGEAL REFLUX; GENERAL PRACTICE; HELICOBACTER PYLORI; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NETHERLANDS; PATIENT COUNSELING; RANDOMIZED CONTROLLED TRIAL;

EID: 0038008471     PISSN: 00187070     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Numans ME, De Wit NJ, Geerdes RHM, Muris IWM, Starmans R, Postema PhJ, et al. NHG-Standaard Maagklachten. Huisarts Wet 1996;39:565-77.
2. Hurenkamp GJB, Grundmeiier HGLM, Bindels PJE, Tytgat GNJ, Van der Hulst RWM. Chronisch gebruik van maagmiddelen in de huisartsenpraktijk in de regio Amsterdam. Ned Tijdschr Geneeskd 1999;143:410-3.
3. Goudie BM, McKenzie PE, Cipriano J, Griffin EM, Murray FE. Repeat prescribing of ulcer healing drugs in general practice-prevalence and underlying diagnosis. Aliment Pharmacol Ther 1996;10:147-50.
4. Ryder SD, O'Reilly S, Miller R, Ross J, Jacyna MR, Levi AJ. Long-term acid suppressing treatment in general practice. BMJ 1994;08:827-30.
5. Gillen D, Wirz AA, Ardill JE, McColl KE. Rebound acid hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology 1999;116:239-47.
6. Weel JF, Van der Hulst RWM, Gerrits Y, Roorda P, Feller M, Dankert I, et al. The interrelation between cytotoxin associated gene A, vacuolating toxin and Helicobacter pylori related diseases. J Infect Dis 1996;173:1171-5.
7. Hurenkamp GIB. Chronic dyspepsia in general practice, tapering the use of acid suppressant drugs [Proefschrift]. Amsterdam: Universiteit van Amsterdam, 2001.
8. El-Omar E, Banerjee S, Wirz BN, Penman I, Ardill JES, McColl KEL. Marked rebound acid hypersecretion after treatment with ranitidine. Am J Gastroenterol 1996;91:355-9.
9. Nwokolo CU, Smith JTL, Sawyerr AM, Pounder RE. Rebound intragastric hyperacidity after abrupt withdrawal of histamine H2 receptor blockade. Gut 1991;32:1455-60.
10. Fullarton GM, McLauchlan G, McDonald A, Crean JP, McColl KEL. Rebound nocturnal hypersecretion after four weeks treatment with an H2 receptor antagonist. Gut 1998;42:159-65.
11. Venables TL, Newland RD, Patel AC, Hole J, Copeman MB, Turbitt ML. Maintenance treatment for gastro-oesophageal reflux disease. A placebo-controlled evaluation of 10 mg omeprazole once daily in general practice. Scand J Gastroenterol 1997;32:627-32.
12. El Serag HB, Sonnenberg A. Associations between different forms of gastro-oesophageal reflux disease. Gut 1997;41:594-9.
13. Dent J, Jones R, Kahrilas P, Talley NJ. Management of gastro-oesophageal reflux disease in general practice. BMJ 2001;322:344-7.
14. Mearin F, Balboa A, Zarate N, Cucala M, Malagelada J-R. Placebo in functional dyspepsia: symptomatic, gastrointestinal motor, and gastric sensorial responses. Am J Gastroenterol 1999;94:116-25.
15. Talley NJ. Drug treatment of functional dyspepsia. Scand J Gastroenterol 1991;26(suppl):47-60.
16. Lanzon-Miller S, Pounder RE, Hamilton MR, Ball S, Chronos NA, Raymond F, et al. Twenty-four hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole. Aliment Pharmacol Ther 1987;1:239-51.